The global regenerative medicine for cartilage market size is expected to grow from $4.83 billion in 2021 to $5.26 billion in 2022 at a compound annual growth rate (CAGR) of 9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The regenerative medicine for cartilage market is expected to reach $7.03 billion in 2026 at a CAGR of 7.5%.
What is the Global Regenerative Medicine For Cartilage Market?
The regenerative medicine for cartilage market consists of sales of regenerative medicines for the cartilage by entities (organizations, sole traders, and partnerships) that have the capacity to grow muscles and organs in the lab and safely implant them when the body cannot regenerate itself, as observed for cartilage tissue after injury or wear. Only goods and services traded between entities or sold to end consumers are included.
Get a Sample of the global regenerative medicine for cartilage market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3961&&type=smp
What drives the Global Regenerative Medicine For Cartilage Market?
The growing incidence of osteoarthritis across the globe will drive the market for regenerative medicine for cartilage. Osteoarthritis is a degenerative joint disorder that mostly attacks the articular cartilage. According to the Arthritis Foundation in 2019, degenerative joint disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Thus, the increasing incidence of osteoarthritis is expected to drive the demand for the cartilage regenerative medicine market.
Get the full global regenerative medicine for cartilage industry report here:
https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report
Global Regenerative Medicine For Cartilage Market Segments
The global regenerative medicine for cartilage market is segmented:
By Treatment Modality: Cell-Based, Non-Cell-Based
By Treatment Type: Palliative, Intrinsic Repair Stimulus, Others
By Site: Knee Cartilage Repair, Ribs, Others
By Application: Hyaline Cartilage Repair and Regeneration, Elastic Cartilage Repair and Regeneration, Fibrous Cartilage Repair and Regeneration
By End-User: Ambulatory Surgical Centers, Hospitals and Clinics, Surgical Centers, Others
By Geography: The regions covered in the regenerative medicine for cartilage market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Regenerative Medicine For Cartilage Global Market Report 2022provides market size and growth forecasts for the global regenerative medicine for cartilage market, global regenerative medicine for cartilage market share, regenerative medicine for cartilage market segments and geographies, regenerative medicine for cartilage market competitive landscape including leading competitors’ revenues, profiles and market shares. The regenerative medicine for cartilage market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Regenerative Medicine For Cartilage Industry Playersinclude B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Vericel Corporation, Stryker Corporation, Smith & Nephew plc, Arthrex Inc., CONMED Corporation, Collagen Solutions PLC, BioTissue Technologies and CellGenix. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
